Home Cart Sign in  
Chemical Structure| 2783-17-7 Chemical Structure| 2783-17-7
Chemical Structure| 2783-17-7

*Storage: Keep in dark place,Inert atmosphere,Room temperature.

*Shipping: Normal

N12N

CAS No.: 2783-17-7

4.5 *For research use only!

Cat. No.: A622495 Purity: 98%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
5g łÇ§¶Ê In Stock In Stock Login
25g łÇò¶Ê In Stock In Stock Login
100g ł§ó¶Ê In Stock In Stock Login
500g łÇÊî¶Ê Inquiry In Stock Login

Please Login or Create an Account to: See VIP prices and availability

  • 5g

    łÇ§¶Ê

  • 25g

    łÇò¶Ê

  • 100g

    ł§ó¶Ê

  • 500g

    łÇÊî¶Ê

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online technical Q&A
Product Citations

Product Details of [ 2783-17-7 ]

CAS No. :2783-17-7
Formula : C12H28N2
M.W : 200.36
MDL No. :MFCD00008155
InChI Key :QFTYSVGGYOXFRQ-UHFFFAOYSA-N
Pubchem ID :17727

Safety of [ 2783-17-7 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H314-H317
Precautionary Statements:P264-P270-P271-P272-P280-P303+P361+P353-P304+P340-P330-P305+P351+P338-P310-P331-P363-P403+P233-P501
Class:8
UN#:3259
Packing Group:

Calculated chemistry of [ 2783-17-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 14
Num. arom. heavy atoms 0
Fraction Csp3 1.0
Num. rotatable bonds 11
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 65.21
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

52.04 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.03
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.8
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.8
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.49
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.87
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.08

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

0.15
Solubility 282.0 mg/ml ; 1.41 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.19
Solubility 308.0 mg/ml ; 1.54 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.02
Solubility 0.019 mg/ml ; 0.0000946 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-8.09 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

1.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.71

Application In Synthesis [ 2783-17-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 2783-17-7 ]

[ 2783-17-7 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 56139-74-3 ]
  • [ 2783-17-7 ]
  • [ 128365-58-2 ]
  • 2
  • [ 2783-17-7 ]
  • [ 5672-83-3 ]
  • [ 501019-77-8 ]
  • 4
  • [ 1585-90-6 ]
  • [ 2783-17-7 ]
  • [ 1297582-73-0 ]
YieldReaction ConditionsOperation in experiment
48.3% In chloroform; for 24h;Reflux; General procedure: N-(2-Hydroxyethyl)maleimide (1) and the diamine (2a-d) were dissolved in 50 mL of chloroform and refluxed for 24 h. The solvent was removed in vacuo. The residue was chromatographed on a silica gel column to afford the desired product.
  • 5
  • [ 2783-17-7 ]
  • [ 6492-86-0 ]
  • [ 1284165-55-4 ]
  • 6
  • [ 2783-17-7 ]
  • [ 6492-86-0 ]
  • [ 1284165-56-5 ]
  • 7
  • [ 2783-17-7 ]
  • [ 18362-30-6 ]
  • [ 1616385-26-2 ]
  • 8
  • [ 2783-17-7 ]
  • [ 18362-30-6 ]
  • [ 1616385-30-8 ]
  • 9
  • [ 2783-17-7 ]
  • [ 28170-07-2 ]
  • [ 66095-20-3 ]
YieldReaction ConditionsOperation in experiment
45% In ethanol; at 65℃; Benzyl carbonate (5 g, 21.9 mmol) was dissolved in 10 ml ethanol and was added dropwise to a solution of 1,12-diaminododecane 48 (4.83 g, 24.1 mmol) in 25 ml ethanol. The resulting mixture was stirred overnight at reflux.After cooling to room temperature, 50 ml of ethanol was added, resulting in a precipitate that was removed byfiltration and washed with 100 ml of ethanol. The ethanol was subsequently concentrated to approximately 10 mland stirred with aqueous HCl (450 ml, 1M) for 30 minutes. The resulting salt was collected by filtration, washedwith 1 M HCl, and stirred for 16 hours in aqueous HCl (250 ml, 1M). The solid was collected by filtration andwashed with diethyl ether (2x 100 ml) and dichloromethane (3x 100 ml). The resulting residue was dissolved in200 ml of dichloromethane and 50 ml of ethanol. This solution was washed twice with 50 ml of a 1 M solutionof sodium hydroxide. The aqueous phase was extracted twice with 50 ml dichloromethane and once with 50 mlof chloroform containing 10 % methanol. The combined organic layers were dried over Na2SO4 en concentratedin vacuo to afford the crude product, which was purified by column chromatography using silica, eluting withdichloromethane containing 10-15% methanol and 1-2% triethylamine yielding the pure product (3.33 g, 45 %).1H NMR (400 MHz, CDCl3): delta 1.15 (s, 2H), 1.26 (m, 16H), 1.45 (m, 4H), 2.65 (t, 2H), 3.18 (q, 2H), 5.08 (s,2H), 7.37 (m, 5H) ppm. 13C NMR (400 MHz, CDCl3): delta 26.58, 26.68, 29.11, 29.64, 29.37, 29.40, 29.68, 32.95,40.80, 41.84, 66.38, 75.60, 75.62, 127.79, 127.88, 128.32, 136.50, 156.77 ppm. RP-LCMS: calc. Mw = 334.3g/mol, found m/z: 335.4 [M+H]+.
  • 10
  • [ 5675-51-4 ]
  • [ 67107-87-3 ]
  • [ 2783-17-7 ]
 

Related Products

Historical Records

Categories